Evidence map›Paper›PMID 21306646›Full record

ArticleBiology direct2011

Enhanced immunogenicity of pneumococcal surface adhesin A (PsaA) in mice via fusion to recombinant human B lymphocyte stimulator (BLyS).

Dennis O Gor, Xuedong Ding, Qing Li, Dilara Sultana, Salamatu S Mambula, Richard J Bram, Neil S Greenspan

Open access · goldAbstract read
In one paragraph

Article in Biology direct, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Human vaccines & immunotherapeutics · 2025
    Review
  3. Review
  4. Microorganisms · 2020
    Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 1 country.

Dennis O GorDepartment of Pathology, Case Western Reserve University School of Medicine, Cleveland, Ohio 44106-4943, USA.
Xuedong Ding
Qing Li
Dilara Sultana
Salamatu S Mambula
Richard J Bram
Neil S Greenspan
Case Western Reserve University · USUniversity School · USBeth Israel Deaconess Medical Center · USMayo Clinic · USMayo Clinic in Florida · US

Funding

TRAINING GRANT IN IMMUNOLOGYT32AI007427 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI LAMM, MICHAEL E. · 1995 to 2004
$877k
IMMUNOGENICITY OF PNEUMOCOCCAL CONJUGATE VACCINESR01AI041657 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI GREENSPAN, NEIL S · 1997 to 2001
$476k
NIAID NIH HHS R01-AI41657NIAID NIH HHS T32-AI07427
6 · The paper itself

Abstract

backgroundB lymphocyte stimulator (BLyS) is a member of the tumor necrosis factor superfamily of ligands that mediates its action through three known receptors. BLyS has been shown to enhance the production of antibodies against heterologous antigens when present at elevated concentrations, supporting an immunostimulatory role for BLyS in vivo.

methodsWe constructed a fusion protein consisting of human BLyS and Pneumococcal Surface Adhesin A (PsaA) and used this molecule to immunize mice. The immunostimulatory attributes mediated by BLyS in vivo were evaluated by characterizing immune responses directed against PsaA.

resultsThe PsaA-BLyS fusion protein was able to act as a co-stimulant for murine spleen cell proliferation induced with F(ab')₂ fragments of anti-IgM in vitro in a fashion similar to recombinant BLyS, and immunization of mice with the PsaA-BLyS fusion protein resulted in dramatically elevated serum antibodies specific for PsaA. Mice immunized with PsaA admixed with recombinant BLyS exhibited only modest elevations in PsaA-specific responses following two immunizations, while mice immunized twice with PsaA alone exhibited undetectable PsaA-specific serum antibody responses. Sera obtained from PsaA-BLyS immunized mice exhibited high titers of IgG1, IgG2a, IgG2b, and IgG3, but no IgA, while mice immunized with PsaA admixed with BLyS exhibited only elevated titers of IgG1 following two immunizations. Splenocytes from PsaA-BLyS immunized mice exhibited elevated levels of secretion of IL-2, IL-4 and IL-5, and a very modest but consistent elevation of IFN-γ following in vitro stimulation with PsaA. In contrast, mice immunized with either PsaA admixed with BLyS or PsaA alone exhibited modestly elevated to absent PsaA-specific recall responses for the same cytokines. Mice deficient for one of the three receptors for BLyS designated Transmembrane activator, calcium modulator, and cyclophilin ligand [CAML] interactor (TACI) exhibited attenuated PsaA-specific serum antibody responses following immunization with PsaA-BLyS relative to wild-type littermates. TACI-deficient mice also exhibited decreased responsiveness to a standard pneumococcal conjugate vaccine.

conclusionThis study identifies covalent attachment of BLyS as a highly effective adjuvant strategy that may yield improved vaccines. In addition, this is the first report demonstrating an unexpected role for TACI in the elicitation of antibodies by the PsaA-BLyS fusion protein. REVIEWERS: This article was reviewed by Jonathan Yewdell, Rachel Gerstein, and Michael Cancro (nominated by Andy Caton).

Indexed as

Adhesins, BacterialAnimalsAntibody FormationBacterial ProteinsB-Cell Activating FactorCytokinesEpitopesHumansImmunizationImmunoglobulinsImmunologic MemoryMiceRecombinant Fusion ProteinsTransmembrane Activator and CAML Interactor ProteinAdhesins, BacterialBacterial ProteinsB-Cell Activating FactorCytokinesEpitopesImmunoglobulinspneumococcal surface protein ARecombinant Fusion ProteinsTnfrsf13b protein, mouseTransmembrane Activator and CAML Interactor Protein

Identifiers

PMID21306646
PMCPMC3055212
OpenAlexW2136926805

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.